TGN1412: the catalyst for change?
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation / Q000379:methods*; D006805:Human Experimentation; D006801:Humans
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C509303:TGN-1412